The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | How can frailty-adapted-therapy improve outcomes in patients with multiple myeloma?
Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses how a formal assessment of frailty, rather than just considering chronological age, significantly alters the treatment plan for patients with multiple myeloma. Dr Rosko notes that patients who are initially frail may improve clinically with intensive treatment, allowing for regimen intensification, or maintain their current regimen if frailty persists. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, I love that question about being able to identify patients as being frail, right? So when we do characterize a patient as being frail, it significantly alters the treatment plan for patients who are newly diagnosed with multiple myeloma and even in the relapse setting. As an example, if a patient is identified to be frail, it changes the type of treatment that a patient is going to receive, the duration of the therapy potentially as well...
Yes, I love that question about being able to identify patients as being frail, right? So when we do characterize a patient as being frail, it significantly alters the treatment plan for patients who are newly diagnosed with multiple myeloma and even in the relapse setting. As an example, if a patient is identified to be frail, it changes the type of treatment that a patient is going to receive, the duration of the therapy potentially as well. But also what we discussed within the session was recognizing that frailty is dynamic and that it’s not a static measure. And so where people start may not be where they end. And so oftentimes for patients who are frail, oftentimes due to their disease, if we provide good intensive treatment for that patient population, then that can also result in patients improving clinically. And so we can intensify their regimen or for patients with ongoing frailty, we can maintain their regimen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
